Travere Therapeutics Inc. (TVTX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Travere Therapeutics Inc. (NASDAQ: TVTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $49.26 (-2.24% 1D, market cap $4.75B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, TVTX ranks #239 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TVTX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -13.0%. By comparison, DNTH (Dianthus Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -30.7%, cap $4.61B) and PTCT (PTC Therapeutics Inc.) posts a C grade (63/100 RQD, P/E 7.9x, ROIC 85.0%, cap $5.01B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).
Per TVTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001438533), Travere Therapeutics Inc. generated $490.7M in revenue (+110.5% YoY), -$25.5M in net income, and $15.7M in free cash flow against $605.2M in total assets and $220.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.44 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 3.2% FCF Margin ($15.7M FCF) & 97.9% Gross Margin
Macro rate sensitivity & RSI-14 (35.8) create a -12 pt regime headwind
While TVTX currently carries a cautious 52/100 (D+) rating due to Macro Regime Fit (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($58.13) and Max Pain ($51.72) forces dealer call-delta covering toward $72.17.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Travere Therapeutics Inc. (TVTX) dropped -2.24% to $49.26, trading at 58% of its 52-week range ($22.59 – $68.73). Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Singapore report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Vanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +110.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on TVTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for TVTX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Travere Therapeutics Inc. (TVTX) ranks #239 by composite RQD confidence (52/100, grade D+) and #167 by equity capitalization ($4.75B). Within this direct 5-issuer industry benchmark cohort, PTCT leads on earnings valuation at 7.9x trailing P/E, while PTCT leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. PTCT currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with TVTX at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TVTX
ACTIVE
Travere Therapeutics Inc. | D+ | 52/100 | — | 96.0% | -13.0% | -2.24% | $4.75B | Benchmark Subject |
| DNTH Dianthus Therapeutics Inc. | D- | 39/100 | — | — | -30.7% | -0.16% | $4.61B | /dnth-vs-tvtx → |
| PTCT PTC Therapeutics Inc. | C | 63/100 | 7.9x | — | 85.0% | +1.52% | $5.01B | /ptct-vs-tvtx → |
| ERAS Erasca Inc. | E | 33/100 | — | — | -35.0% | -2.09% | $5.02B | /eras-vs-tvtx → |
| EWTX Edgewise Therapeutics Inc. | D- | 41/100 | — | — | -31.9% | -2.03% | $4.22B | /ewtx-vs-tvtx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Travere Therapeutics Inc. (TVTX) reported GAAP revenue of $490.7M (+110.5% vs. FY2024 revenue of $233.2M , and +237.9% cumulative change since FY2023) , GAAP net income of -$25.5M, operating cash flow of $37.8M, and free cash flow of $15.7M (+106.3% YoY). On the balance sheet, TVTX closed FY2025 with $605.2M in total assets against $220.7M in total debt (Altman Z-Score: 3.44, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $490.7M | -$25.5M | $37.8M | $15.7M | $605.2M | $220.7M |
| FY2024 (FY) | 2024-12-31 | $233.2M | -$321.5M | -$237.5M | -$248.0M | $594.1M | $240.8M |
| FY2023 (FY) | 2023-12-31 | $145.2M | -$111.4M | -$280.0M | -$286.6M | $2.62B | $613.5M |
As of 2026-11-03, Travere Therapeutics Inc. (NASDAQ: TVTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $49.26 (-2.24% 1D, market cap $4.75B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, TVTX ranks #239 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TVTX carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -13.0%. By comparison, DNTH (Dianthus Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -30.7%, cap $4.61B) and PTCT (PTC Therapeutics Inc.) posts a C grade (63/100 RQD, P/E 7.9x, ROIC 85.0%, cap $5.01B). Among the 5-stock peer group, PTCT leads on earnings multiple (7.9x) while PTCT leads on capital efficiency (85.0% ROIC).
Per TVTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001438533), Travere Therapeutics Inc. generated $490.7M in revenue (+110.5% YoY), -$25.5M in net income, and $15.7M in free cash flow against $605.2M in total assets and $220.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
TVTX last traded at $49.26 (-2.24% on volume of 2,905,275 shares), positioning the stock -15.26% below its 50-day simple moving average ($58.13) and +4.92% above its 200-day simple moving average ($46.95). Across its 52-week range of $22.59 to $68.73, TVTX sits at the 57.8% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±7.7% ($45.47 to $53.05).
Travere Therapeutics Inc. (TVTX) earns a live Roarable RQD composite score of 52/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $49.26 (-2.24% 1D, market capitalization $4.75B).
Travere Therapeutics Inc. (TVTX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe specific products, customers, or revenue mechanics. Gross margin is reported at 96% which indicates high gross profitability on reported revenue.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Travere Therapeutics Inc. (TVTX) reported $490.7M in annual revenue (up from $233.2M in FY2024, +110.5% YoY) and -$25.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($145.2M revenue, -$111.4M net income) through FY2025, TVTX scaled operating cash flow to $37.8M and free cash flow to $15.7M, backed by $605.2M in total assets against $220.7M in total debt.
Upstream and downstream dependencies are — Sector correlations and 2nd-order bottlenecks cannot be mapped from the provided material. An investor should note that the absence of graph linkage is a data gap, not evidence of independence from suppliers or partners.
Real-time company headlines, analyst actions, and sector developments for Travere Therapeutics Inc. (TVTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Pluang report covering Travere Therapeutics Inc. (TVTX) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on TVTX here at $50.39: Revenue grew from $145.2M in FY 2023 to $490.7M in FY 2025 and FY 2025 FCF turned positive at $15.7M, with a 96% gross margin and a Piotroski F-Score of 7/9.. Compare TVTX's -12.8% operating margin and -13.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $47.87 are getting bought.
@RedlineAuditor Shorting a 8/20 institutional whale-flow stock at $50.39 is dangerous when funds are rotating into Health Care.
ROIC is -13%, operating margin is -12.8%, FCF yield is 0.33%, and Debt/Equity is 1.79, with the RQD composite at 52 (D+).. Look at the math on TVTX: paying 18.0x forward P/E for -13.0% ROIC and -12.8% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $44.34 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).